Tracking patient consent for the use of their samples in clinical trials is essential to both minimize risk of non-compliance and maximizing potential for future use.
In this episode, Barbara Nagaraj, Sr. IT Architect at BioFortis, a IQVIA Laboratories company, explains informed consent for patient samples and the importance of easily tracking consent as samples move through the clinical trial ecosystem.
She describes:
- How consent is or has been documented
- The benefits of electronic consent documentation
- Specific consent attributes, e.g. genetic testing
- Handling consent requirements from different countries or institutions
- Understanding consent for future use, including limitations and expirations
Related Insights
Managing Informed Consent Samples from Clinical Trials
A set of best practices for the definition, tracking and management of allowable use attributes associated with samples collected in protocol based clinical trials
Consent Tracking for Clinical Trial Samples
Optimizing the management of consents throughout the entire lifecycle
Tracking Clinical Trial Samples
Optimizing the management of samples throughout the entire lifecycle
Blockchain in Clinical Research Sample Management
Distributed Ledger Technology (DLT) in clinical trials
Managing Sample Data from Vendors
Best Practices for Clinical Trials
Using Labmatrix® at a Big Biopharma Company to Reduce Clinical Trial Delays, Costs and Regulatory Risks
Managing Sample Data from Vendors
Best practices for clinical trials
eConsent and BioBanking
How to reduce costs while improving efficiencies
Key Central Laboratory Capabilities to Enable Successful Immuno-Oncology Clinical Development
Trends and recommendations in laboratory selection
